

External Quality Assessment Program for

## Alzheimer's disease biomarkers

Labquality, an independent provider of External Quality Assessment (EQA) schemes with over 50 years of experience, is planning to organize an EQA pilot study for Alzheimer's disease biomarkers. In order to determine the level of interest for this program, we would appreciate your participation in our online survey. Your response will provide valuable information for the development of our EQA programs.

According to current plans, the pilot study would comprise two artificial cerebrospinal fluid samples with normal and abnormal concentrations of the biomarkers p-tau, p-tau217, t-tau, and amyloid- $\beta$ , along with two serum samples containing normal and abnormal levels of neurofilament. Adjustments to the sample matrix may be made as required.

### Alzheimer's disease biomarkers

- Samples:** 2 CSF samples  
Markers: p-tau, p-tau217, t-tau, and amyloid- $\beta$
- 2 serum samples  
Markers: neurofilament
- Distribution:** 2026
- Registration:** Please send your response to this query by [this link](#) or by scanning this QR code no later than 31.3 2026.



### For more information

Labquality's customer service [info@labquality.com](mailto:info@labquality.com) or

**Päivi Ranta**  
EQA Coordinator  
[paivi.ranta@labquality.com](mailto:paivi.ranta@labquality.com)  
+358 45 773 107 80

**Heidi Berghäll**  
EQA Solution manager, R&D  
[heidi.berghall@labquality.com](mailto:heidi.berghall@labquality.com)  
+358 50 356 0503